Table 2.
IGSF9 expression and survival correlation in TCGA RNA-seq dataset.
| Abbrev. | Cancer type | Sample size(1) | Expression level(2) | Overall survival(3) |
|---|---|---|---|---|
| BLCA | Bladder urothelial carcinoma | Normal (n = 19) Tumor (n = 408) |
Up | - |
| BRCA | Breast invasive carcinoma | Normal (n = 114) Tumor (n = 1094) |
Up | - |
| CESC | Cervical squamous cell carcinoma and endocervical adenocarcinoma | Normal (n = 3) Tumor (n = 305) |
Up | - |
| CHOL | Cholangiocarcinoma | Normal (n = 9) Tumor (n = 36) |
Up | - |
| COAD | Colon adenocarcinoma | Normal (n = 41) Tumor (n = 286) |
Down | - |
| HNSC | Head and neck squamous cell carcinoma | Normal (n = 44) Tumor (n = 520) |
Up | - |
| LGG | Brain lower grade glioma | Grade II (n = 248) Grade III (n = 265) |
- | Yes |
| LUSC | Lung squamous cell carcinoma | Normal (n = 59) Tumor (n = 515) |
Up | - |
| READ | Rectum adenocarcinoma | Normal (n = 11) Tumor (n = 166) |
Down | - |
| SKCM | Skin cutaneous melanoma | Normal (n = 1) Tumor (n = 472) |
- | Yes |
| THCA | Thyroid carcinoma | Normal (n = 60) Tumor (n = 505) |
Up | - |
| THYM | Thymoma | Normal (n = 2) Tumor (n = 121) |
- | Yes |
| UCEC | Uterine corpus endometrial cancer | Normal (n = 35) Tumor (n = 546) |
Up | Yes |
Notes. (1)The number of normal versus tumor samples, except for LGG. (2)“Up” or “Down” indicates significant expression level changes, tumor versus normal; dash indicates no significant change. (3)Kaplan-Meier analysis; “Yes” indicates that higher expression of IGSF9 is related to poor overall survival.